Taking advantage of the fact that IL-1 antagonism is approved in several countries for the treatment of gout and rheumatoid arthritis, clinicians may already use this anti-inflammatory strategy in the presence of concomitant type 2 diabetes. Here, IL1A is linked to rheumatoid arthritis.